AGP Executive Report
Last update: 4 hours agoCancer Partnerships: AbbVie agreed to pay Disco Pharmaceuticals up to $2.5 billion to develop bispecific cancer therapies for solid tumors. Merck also teamed with AI drug-design firm Isomorphic Labs to find oncology medicines. Cell Therapy: Pfizer signed a deal worth up to $2.6 billion for rights to three early-stage in vivo CAR-T programs targeting autoimmune diseases. New Treatment: The FDA approved Livsayis, the first siRNA therapy for generalized myasthenia gravis, with dosing four times a year. Drug Pricing: India’s pharma industry body backed a cap on cancer-drug trade margins but urged the government to avoid abrupt price cuts that could unsettle investment. Manufacturing Growth: Ghana reaffirmed a $1 billion pharmaceutical and biomanufacturing investment; Ethiopia’s drug market could more than double to $3.6 billion by 2030, an industry association projects.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.